Protocol Ledger

NCT04570332 · Phase II · COMPLETED

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

Interventional Phase II clinical trial protocol NCT04570332 sponsored by Highlight Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-30 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04570332
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04570332
Protocol FieldVerified Registry Value
NCT IdentifierNCT04570332
Consolidated Lead SponsorHighlight Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2020-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04570332
Hospital Research SiteLocationSite Profile
Hospital Clinic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->
Hospital General Universitario Gregorio MarañónMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI